Record mula sa primary source
Decision-gradeTopline na resulta
Quince Therapeutics: Phase 3 NEAT topline readout para sa eDSP sa A-T inaasahan sa Q1 2026
Nakumpleto na ng kumpanya ang enrollment ng pivotal Phase 3 NEAT trial (105 kabuuang kalahok) at nakumpirma na ang topline results ay irereport sa Q1 2026. Ang trial ay nananatili sa ilalim ng FDA Special Protocol Assessment, at ang positibong data ay susuporta sa isang NDA submission na binalak para sa H2 2026.
Mahahalagang fact
- Na-file
- Nob 12, 2025, 09:05 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
QNCXQuince Therapeutics, Inc.- Asset
- eDSP
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Istatistikal na kapangyarihan
- ~90%
- Mga kalahok
- 105
- Paglahok sa OLE
- 100%
- Populasyon ng pangunahing pagsusuri
- 83
Sipi mula sa source
EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report